Company Description
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally.
It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol.
The company’s testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time.
It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children’s drug use.
The company was incorporated in 1986 and is headquartered in Dallas, Texas.
| Country | United States |
| Founded | 1986 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Brian Hullinger |
Contact Details
Address: 5220 Spring Valley Road, Suite 230 Dallas, Texas 75254 United States | |
| Phone | 800 527 7424 |
| Website | psychemedics.com |
Stock Details
| Ticker Symbol | PMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000806517 |
| CUSIP Number | 744375205 |
| ISIN Number | US7443752057 |
| Employer ID | 58-1701987 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Brian Hullinger | President, Chief Executive Officer and Director |
| Daniella Mehalik | Vice President of Finance |
| Shannon Shoemaker | Vice President and Chief Revenue Officer |
| Dr. Werner A. Baumgartner Ph.D. | Founder |
| Annette Baumgartner | Founder |
| Michael Weisenhoff | Principal Financial and Accounting Manager |
| Patrick J. Kinney Jr. | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 8, 2024 | ARS | Filing |
| Oct 18, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |
| Oct 18, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 16, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |
| Oct 16, 2024 | PRER14A | Filing |
| Oct 4, 2024 | SC 13E3/A | [Amend] Going private transaction by certain issuers |
| Oct 4, 2024 | PRER14A | Filing |